Pariet: Advanced Acid Control for Lasting Gastric Relief
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.41 | $36.98 (0%) | 🛒 Add to cart |
| 120 | $0.39 | $49.31 $46.44 (6%) | 🛒 Add to cart |
| 180 | $0.37 | $73.96 $66.22 (10%) | 🛒 Add to cart |
| 270 | $0.35 | $110.94 $95.46 (14%) | 🛒 Add to cart |
| 360 | $0.34
Best per pill | $147.92 $123.84 (16%) | 🛒 Add to cart |
Pariet (rabeprazole sodium) is a proton pump inhibitor (PPI) engineered for superior and sustained suppression of gastric acid production. It is clinically indicated for the treatment of a range of acid-related disorders, offering a targeted mechanism of action that promotes healing and provides symptomatic relief. This medication works by irreversibly binding to the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) at the secretory surface of the gastric parietal cell, thereby effectively blocking the final step of acid production. Its optimized pharmacokinetic profile ensures a rapid onset of action and consistent 24-hour acid control, making it a cornerstone therapy in gastroenterology for both short-term and maintenance treatment regimens.
Features
- Active Pharmaceutical Ingredient: Rabeprazole sodium.
- Drug Class: Proton pump inhibitor (PPI).
- Available Strengths: 10 mg and 20 mg enteric-coated tablets.
- Mechanism of Action: Selective and irreversible inhibition of the H+/K+ ATPase enzyme (proton pump).
- Pharmacokinetics: Rapid absorption; not significantly affected by food intake. Extensive first-pass metabolism in the liver primarily via non-enzymatic reduction and CYP3A4/CYP2C19 pathways.
- Formulation: Delayed-release tablet designed to dissolve in the small intestine to protect the active ingredient from degradation by stomach acid.
Benefits
- Achieves profound and prolonged suppression of gastric acid secretion, creating an optimal environment for the healing of erosive and ulcerative lesions.
- Provides rapid and effective relief from heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
- Effective in eradicating Helicobacter pylori (H. pylori) infection when used in combination with antibiotics, reducing the risk of ulcer recurrence.
- Offers a favorable safety and tolerability profile for both acute and long-term maintenance therapy in appropriate patient populations.
- Consistent 24-hour pharmacodynamic effect allows for convenient once-daily dosing, supporting patient adherence to treatment regimens.
Common use
Pariet is prescribed for the treatment of conditions where the reduction of gastric acid is therapeutic. These include: healing and maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD); treatment of symptomatic GERD; healing of duodenal ulcers and gastric ulcers; treatment of Helicobacter pylori (H. pylori) infection in combination with antibiotics (e.g., amoxicillin and clarithromycin) for the eradication of the bacteria in patients with duodenal ulcer disease or a history of duodenal ulcer; and treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Dosage and direction
The dosage of Pariet is individualized based on the specific condition being treated and patient response. It must be taken as directed by a physician.
- For GERD (Healing of Erosive GERD & Symptomatic GERD): The recommended adult oral dose is 20 mg once daily for 4 to 8 weeks. For maintenance healing, 10 mg or 20 mg once daily may be used.
- For Duodenal Ulcers: The recommended adult oral dose is 20 mg once daily after the morning meal for a period of up to 4 weeks.
- For H. pylori Eradication: The recommended adult oral dose is 20 mg twice daily, taken with meals, in combination with amoxicillin 1000 mg and clarithromycin 500 mg, each taken twice daily for 7 days.
- Administration: The tablet should be swallowed whole with a glass of water. It should not be crushed, chewed, or split, as this will damage the enteric coating and compromise the drug’s efficacy. Pariet can be taken with or without food.
Precautions
- Pariet may mask the symptoms of gastric malignancy. Therefore, the presence of gastric malignancy should be excluded before initiating therapy with rabeprazole, as treatment may alleviate symptoms and delay diagnosis.
- Use with caution in patients with severe hepatic impairment, as metabolism may be decreased. Consider a dose adjustment in these patients.
- Proton pump inhibitors (PPIs) like Pariet have been associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), particularly in hospitalized patients. Consider this diagnosis in patients who develop diarrhea that does not improve.
- Long-term PPI therapy has been associated with hypomagnesemia (low magnesium levels). This may present with symptoms such as tetany, arrhythmias, and seizures. Monitoring of magnesium levels should be considered prior to initiation of long-term therapy and periodically thereafter.
- PPI use may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. The risk appears to be highest in patients receiving high-dose, long-term therapy. Use the lowest effective dose for the shortest duration appropriate to the condition being treated.
- Avoid concomitant use of Pariet with atazanavir or rilpivirine, as significant reductions in their plasma concentrations may occur, compromising their antiviral efficacy.
Contraindications
Pariet is contraindicated in patients with known hypersensitivity to rabeprazole, any substituted benzimidazoles, or to any excipients in the formulation. It is also contraindicated for co-administration with drugs whose absorption is highly pH-dependent and where a significant reduction in efficacy is well-documented, such as atazanavir and rilpivirine.
Possible side effect
Like all medicines, Pariet can cause side effects, although not everybody gets them. Common side effects (may affect up to 1 in 10 people) include headache, diarrhea, nausea, vomiting, constipation, abdominal pain, flatulence, and dizziness. Uncommon side effects (may affect up to 1 in 100 people) include insomnia, cough, pharyngitis, rhinitis, bronchitis, back pain, flu-like syndrome, and rash. Rare but serious side effects require immediate medical attention and can include signs of a severe allergic reaction (e.g., swelling of the face, lips, tongue, or throat, difficulty breathing, severe skin reactions), signs of kidney problems (e.g., changes in urination), severe diarrhea with weakness and fever, or symptoms of low magnesium (e.g., muscle spasms, tremors, cramps, fatigue, confusion, seizures, dizziness, irregular heartbeat).
Drug interaction
Pariet can alter the absorption or metabolism of other drugs due to its profound effect on gastric pH and its metabolism via the CYP450 system.
- Drugs Dependent on Gastric pH for Absorption: Pariet may reduce the absorption of drugs that require an acidic gastric environment for optimal bioavailability, such as ketoconazole, itraconazole, and iron salts.
- Warfarin: Concomitant administration of PPIs with warfarin may potentiate its anticoagulant effect and increase the risk of bleeding. Monitoring of INR and prothrombin time is recommended.
- Methotrexate: Some PPIs have been reported to increase methotrexate levels when administered concurrently. Caution is advised with high-dose methotrexate.
- CYP2C19 Substrates: Rabeprazole is a weak inhibitor of CYP2C19 and may increase the systemic exposure of drugs metabolized by this enzyme (e.g., phenytoin).
- Digoxin: A slight increase in digoxin exposure has been observed; monitoring of digoxin levels is advisable.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered on that day. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to make up for a forgotten dose.
Overdose
Experience with rabeprazole overdose is limited. Reported symptoms are consistent with the known safety profile of the drug and may include signs of hypotension, confusion, drowsiness, blurred vision, tachycardia, nausea, sweating, flushing, headache, and dry mouth. Specific antidotes are not known. Rabeprazole is extensively protein-bound and is, therefore, not readily dialyzable. Treatment should be symptomatic and supportive.
Storage
Store at room temperature (15°C to 30°C or 59°F to 86°F) in a dry place, protected from light and moisture. Keep the blister strips in the original carton until use. Keep all medicines out of the sight and reach of children. Do not use this medicine after the expiry date printed on the carton and blister.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided may not cover all possible uses, directions, precautions, drug interactions, or adverse effects.
Reviews
- “As a gastroenterologist, I find Pariet to be a highly effective and reliable PPI for managing severe GERD. Its consistent acid suppression provides predictable healing outcomes for my patients with erosive esophagitis.” – Dr. A. Sharma, MD
- “The 7-day H. pylori eradication regimen with Pariet-based triple therapy has shown excellent success rates in my practice, significantly reducing ulcer recurrence.” – Clinical Pharmacist
- “Switched to Pariet after another PPI caused persistent headaches. This has been effective for my acid reflux with no side effects for over a year now.” – Patient M.T.
- “While effective, it’s crucial to periodically reassess the need for long-term PPI therapy in patients on maintenance dosing to mitigate potential long-term risks.” – Dr. L. Chen, Gastroenterologist